Dr. Yue Lu: A Review and Update on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Dr. Yue Lu: A Review and Update on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a rare malignancy of the hematopoietic system, is distinguished by its highly recognizable skin manifestations and complex pathophysiology, which continue to captivate the medical community's investigative spirit and challenge its resolve. Recently, Dr. Yue Lu from Lu Daopei Medical provided an in-depth analysis of BPDCN's origins, clinical presentation, diagnostic methods, and treatment advancements, shedding light on the cutting-edge developments in this field. The following article, based on his insights, has been prepared by Hematology Frontier for our readers.
Mutual Learning Between China and Germany丨International Perspectives, Leading the Frontier: The Academic Journey of Dr. Jürgen Wolf from the Universit

Mutual Learning Between China and Germany丨International Perspectives, Leading the Frontier: The Academic Journey of Dr. Jürgen Wolf from the Universit

With an international perspective and a focus on leading-edge advancements, the Overseas Experts China Tour project welcomed a prominent figure in the field of lung cancer from August 5th to 10th, 2024—Dr. Jürgen Wolf, Director of the Centre for Integrated Oncology (CIO) at University Hospital of Cologne, Professor of Interdisciplinary Translational Oncology at the University of Cologne, and Head of the CIO Lung Cancer Program. During his five-day academic exchange tour in China, Professor Wolf visited Chengdu, Hangzhou, Changsha, and Qingdao, attracting lung cancer experts from across the country for discussions and exchanges. Throughout these academic activities, Professor Wolf not only shared the experiences of lung cancer diagnosis and treatment in Germany but also engaged in vigorous academic discussions with Chinese experts on the latest advancements and contentious topics in lung cancer treatment, sparking many brilliant ideas.
Dr. Zhizhong Pan: The Journey of Colorectal Cancer Immunotherapy Research—Experiences from Sun Yat-sen University Cancer Center丨Guangzhou Colorectal Cancer Summit Forum

Dr. Zhizhong Pan: The Journey of Colorectal Cancer Immunotherapy Research—Experiences from Sun Yat-sen University Cancer Center丨Guangzhou Colorectal Cancer Summit Forum

At the Guangzhou Colorectal Cancer Summit Forum and the 22nd Guangdong Colorectal Cancer Academic Conference held from August 5-10, 2024, Dr. Zhizhong Pan from Sun Yat-sen University Cancer Center delivered an insightful presentation titled "The Journey of Colorectal Cancer Immunotherapy Research: Experiences from Sun Yat-sen University Cancer Center." After the conference, Professor Pan granted us an interview, and we have compiled the content below for our readers.
Insights from Hematology Expert | Dr. Jianxiang Wang: Delving into Immune Mechanisms to Pioneer New Target Frontiers

Insights from Hematology Expert | Dr. Jianxiang Wang: Delving into Immune Mechanisms to Pioneer New Target Frontiers

The breakthrough achievements of CAR-T therapy in the field of hematologic malignancies are remarkable. However, challenges such as target limitations, limited cell sources, and durability of efficacy continue to necessitate further exploration. Dr. Jianxiang Wang's team at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences , stands as a pioneer in the field of immunotherapy, advancing both basic and clinical research to push the boundaries of hematologic cancer immunotherapy. In this issue of Hematology Frontier, Dr. Jianxiang Wang shares the research outcomes and forward-looking insights of his team in the realm of immunotherapy. The aim is to inspire new clinical thinking and collaboratively open a new chapter in hematologic cancer immunotherapy, bringing more hope and possibilities to patients.
Dr. Ruiyun Zhang: New Approaches Like Targeted Immunotherapy and ctDNA Further Address the Bladder-Preserving Needs of MIBC Patients | 2024 ASCOBT

Dr. Ruiyun Zhang: New Approaches Like Targeted Immunotherapy and ctDNA Further Address the Bladder-Preserving Needs of MIBC Patients | 2024 ASCOBT

The ASCO Breakthrough Summit, held from August 8th to 10th in Yokohama, Japan, focused on new technologies in cancer treatment and shared breakthrough advances and research that are driving global cancer treatment forward. The research titled "Preliminary results of an open-label, single-arm, multi-center study on disitamab vedotin (DV) combined with toripalimab and radiotherapy as bladder-preserving therapy in HER2 overexpression muscle-invasive bladder cancer (MIBC; DECIDING study-stage I)" by Dr. Haige Chen and Dr. Ruiyun Zhang from Renji Hospital, Shanghai JiaoTong University School of Medicine, was selected for presentation. Urology Frontier invited Dr. Ruiyun Zhang to discuss the treatment needs of MIBC patients, the DECIDING study results, progress in ctDNA, and the team's ongoing explorations.
Dr. Erlie Jiang: Exploring Stem Cell Transplantation Strategies for Adult Acute Lymphoblastic Leukemia |The 8th CSCO Hematology Academic Conference

Dr. Erlie Jiang: Exploring Stem Cell Transplantation Strategies for Adult Acute Lymphoblastic Leukemia |The 8th CSCO Hematology Academic Conference

To further enhance the diagnosis and treatment of leukemia and lymphoma in China, the 8th Hematology Academic Conference, jointly organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and CSCO Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was grandly held in Harbin from July 26 to 28, 2024. On this occasion, "Oncology Frontier - Hematology Frontier" invited Dr. Erlie Jiang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to discuss the frontier topic of hematopoietic stem cell transplantation (HSCT).
Dr. Jun Ma: Gathering Global Experts to Discuss Cutting-Edge Advances and Core Concepts | The 8th CSCO Annual Hematology Conference

Dr. Jun Ma: Gathering Global Experts to Discuss Cutting-Edge Advances and Core Concepts | The 8th CSCO Annual Hematology Conference

In the sweltering summer, we gather in Ice City. The “8th Annual Hematology Conference” organized by the Chinese Society of Clinical Oncology (CSCO), the CSCO Leukemia Expert Committee, and the CSCO Lymphoma Expert Committee, and hosted by the Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was grandly held in Harbin from July 26 to 28, 2024. Renowned experts and scholars from both domestic and international arenas came together to present and discuss research in leukemia, lymphoma, and myeloma, as well as address hot topics in clinical practice. On the first day of the conference, we were honored to interview Dr. Jun Ma, the conference chairman and director of the Harbin Institute of Hematology and Oncology, to share the hi